FilingReader Intelligence
Zydus gets tentative US approval for cancer drug
July 24, 2025 at 07:09 AM UTC•By FilingReader AI
Zydus Lifesciences announced tentative US FDA approval for Ibrutinib tablets, a kinase inhibitor for chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia.
The tablets recorded annual US sales of $2.15bn as of May 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:ZYDUSLIFE•Bombay Stock Exchange
News Alerts
Get instant email alerts when Zydus Lifesciences publishes news
Free account required • Unsubscribe anytime